Desk screen

Desk Screen Report

Summary Assessment

This is a substantial empirical research manuscript reporting spatial transcriptomic analysis of rheumatoid arthritis synovial tissue, combined with mechanistic cell culture and ex vivo tissue studies. The work proposes that fibroblast-derived neurotrophin signaling drives pathological vascular maturation in RA, and demonstrates that FDA-approved TRK inhibitors can reverse this process in tissue explants.

Scope and Venue Fit

The manuscript is in scope for In Silico:

• Original research with testable claims
• Empirical work combining high-dimensional spatial transcriptomics with functional validation
• Central evidence is presented in the manuscript and supplementary figures
• Claims are specific and evaluable from the data shown

The work is appropriate for a broad research audience: immunologists and rheumatologists will recognize the clinical relevance, while cell biologists, vascular biologists, and computational researchers can evaluate the mechanistic and methodological contributions independently.

Threshold Issues

No fundamental barriers to review:

1. Completeness: The manuscript is complete. Methods are detailed (Materials and Methods section is thorough), data are presented, and claims are bounded.

2. Intelligibility: The manuscript is clearly written. The narrative is logical: observation of persistent vascular maturation → identification of neurotrophin signaling → mechanistic dissection → therapeutic validation.

3. Evidence accessibility:

   • Spatial transcriptomic data from 46 samples (22 RA patients + 2 healthy donors) are analyzed
   • Cell culture, co-culture, and tissue explant experiments are described with sufficient detail
   • Supplementary figures provide supporting evidence
   • No claim appears to rest on inaccessible data

4. Not a clinical guidance document: This is basic/translational research, not a clinical trial or treatment recommendation. The TRK inhibitor work is exploratory ex vivo validation, not a clinical protocol.

Potential Concerns (Not Desk-Reject Level)

These are substantive questions for reviewers, not reasons to reject without review:

• Causality vs. association: The spatial transcriptomics is correlative. While the functional studies (siRNA, pharmacologic inhibition, agonists) support a causal role for neurotrophin signaling, the strength of evidence for NOTCH3→NGF→NGFR→mural cell differentiation as a complete pathway could be scrutinized.

• Generalizability of ex vivo findings: Synovial explants are cultured for only 3 days. Whether the effects of TRK inhibitors would persist in longer cultures or translate to in vivo RA models is not addressed (though this is acknowledged as future work).

• Treatment-resistant mechanism: The claim that neurotrophin signaling explains treatment resistance is supported by the observation that vascular maturation persists post-treatment, but the manuscript does not directly show that blocking neurotrophin signaling restores responsiveness to conventional DMARDs or TNFi.

• Statistical rigor: Most comparisons use appropriate tests (Wilcoxon, ANOVA with Bonferroni correction), but some analyses involve multiple comparisons across many genes/cell types. The multiple-testing burden is not fully transparent in all figures.

• NOTCH3 specificity: The role of NOTCH3 is demonstrated in fibroblasts, but whether NOTCH3 in endothelial cells or other cell types contributes is not fully explored.

These are all legitimate questions for peer review, not fatal flaws.

Strengths Supporting Proceeding

• Novel mechanistic insight: Coupling of NOTCH3 and neurotrophin signaling in vascular maturation is not previously described in RA.
• Multi-level validation: Spatial transcriptomics → single-cell RNA-seq → RNAscope → immunohistochemistry → functional assays (siRNA, pharmacology, organoids).
• Therapeutic angle: Repurposing FDA-approved drugs (larotrectinib, entrectinib) is clinically relevant.
• Longitudinal design: Pre- and post-treatment paired biopsies strengthen the observation of persistent vascular maturation.
• Reproducible methods: Detailed protocols, standard tools (Xenium, Seurat, standard markers), and appropriate statistical approaches.

Recommendation

The manuscript meets the threshold for full review. The central claims are specific and testable, the evidence is presented and accessible, and the work will be of interest to researchers in immunology, vascular biology, and rheumatology. Reviewers will have substantive questions about mechanism and translation, but these are appropriate for peer review, not grounds for desk rejection.

---

DESK DECISION: proceed

Send to full review panel.